Real world evidence of nivolumab in Japanese patients with head and neck cancer-Reference-Cited by-同舟云学术

Real world evidence of nivolumab in Japanese patients with head and neck cancer

Published:2022 Issue:1 Volume:48 Page:1-6
ISSN:1349-5747
Container-title:Toukeibu Gan
language:en
Short-container-title:Toukeibu Gan

Author:

Homma Akihiro¹,Kaneko Hirokazu²,Endo Toshimitsu³

Affiliation:

1. Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University

2. Oncology Medical, Bristol-Myers Squibb K.K.

3. Oncology Medical Affairs, Ono Pharmaceutical Co. Ltd.

Publisher

Japan Society for Head and Neck Cancer

Subject

Oncology,Otorhinolaryngology

Link

https://www.jstage.jst.go.jp/article/jjhnc/48/1/48_1/_pdf

Reference37 articles.

1. 1） Vermorken J.B., Mesia R., Rivera F., et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359（11）：1116-1127, 2008

2. 2） Hanai N., Shimizu Y., Kariya S., et al: Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real‑world clinical practice: a multicenter retrospective clinical study. Int J Clin Oncol 26（3）：494-506, 2021

3. 3） Kariya S., Shimizu Y., Hanai N., et al: Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting. Int J Clin Oncol 26（6）：1049-1056, 2021

4. 4） Yasumatsu R., Shimizu Y., Hanai N., et al: Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study. Int J Clin Oncol Accepted

5. 5） Minohara K., Matoba T., Kawakita D., et al: Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab. Sci Rep 11（1）：16992, 2021